QPS Netherlands ready to take on clinical trials that require relocation, manage new projects.
According to a recent report by Fitch Solutions, Brexit is already impacting the UK’s clinical trials environment.
The number of clinical trials taking place in the UK has declined by more than 25 per cent since British voters elected to leave the EU in 2016.
With Brexit pending and the European Medicines Agency (EMA) headquarters moving from London to the Netherlands, QPS, a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services, announced it is ready to take on clinical trials that need to relocate and is prepared to manage new projects in the Netherlands, Austria and around the globe.
“There are concerns about how medicines will be approved in the UK after Brexit, as well as how MHRA will operate as a stand-alone agency and how the EMA will manage data generated in the UK. As a result, companies are beginning to suspend clinical trial activities across the UK,” said Marc Thouin, president and general manager of QPS in the Netherlands.
The Netherlands is a great location to host a clinical research site, as it is home the new EMA headquarters, is a top R&D innovation hub for biopharmaceutical companies, has one of the world’s highest-ranking healthcare systems, several research institutes, and more than 100 biotech companies. [APBN]